Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, ...

Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the ...

It is set to report its Q4 2024 earnings on Feb. 4, before the market opens ... could have declined to $8,858 from stock price depreciation. However, Pfizer also paid dividends during these ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and its stock remained flat after market open. Pfizer reported $63.6 ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... if investors are hoping for a rising stock market, what would they want to see? Cramer explained that a job report ...

Today, Benzinga's options scanner spotted 33 options trades for Pfizer. This is not a typical pattern. The sentiment among these major traders is split, with 66% bullish and 33% bearish. Among all the ...